- Home
- / VBL Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
VBL Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.2
2023-10-16
Market Capitalization
$12.1 M
2023-10-16
Revenue
$310 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 585.0K | 562.0K | 922.0K | 768.0K | 658.0K | 310.0K |
| Cost of goods sold | 235.0K | 144.0K | 394.0K | 365.0K | 104.0K | 197.0K |
| Gross profit | 350.0K | 418.0K | 528.0K | 403.0K | 554.0K | 113.0K |
| Gross profit margin, % | 74.4% | 57.3% | 52.5% | 84.2% | 36.5% | |
| Operating expense total | 20.4M | 18.7M | 23.8M | 29.1M | 32.3M | 14.5M |
| Depreciation and amortization | 1.2M | 1.7M | 1.2M | 1.3M | 1.1M | 257.0K |
| EBITDA | (20.1M) | (18.3M) | (23.3M) | (28.7M) | (31.8M) | (14.4M) |
| EBITDA margin, % | -3256.2% | -2525.9% | -3742.2% | -4832.1% | -4645.2% | |
| EBIT | (21.2M) | (20.0M) | (24.5M) | (30.0M) | (32.9M) | (14.5M) |
| EBIT margin, % | -3561.2% | -2655.4% | -3905.7% | -4992.9% | -4670.3% | |
| Interest income | 908.0K | 870.0K | 363.0K | 120.0K | 634.0K | |
| Interest expense | 122.0K | 313.0K | 105.0K | 44.0K | 85.0K | |
| Pre tax profit | (20.5M) | (19.5M) | (24.2M) | (29.9M) | (32.3M) | (11.3M) |
| Net Income | (20.5M) | (19.5M) | (24.2M) | (29.9M) | (32.3M) | (11.3M) |